Findings and Change in Management Associated with NaF PET by Indication
| IS | FOM | POM | |||||||||
| Indication | Breast | NSCLC | Other | Prostate | Breast | NSCLC | Other | Prostate | Breast | Other | Prostate |
| Scans by indication (n) | 181 | 166 | 223 | 2,301 | 781 | 380 | 653 | 4,686 | 199 | 236 | 1,297 |
| NaF PET findings (%) | |||||||||||
| Benign | 72.4 | 59.6 | 70.9 | 71.9 | 62.1 | 54.2 | 57.1 | 53.3 | 14.6 | 18.2 | 15.0 |
| Equivocal | 4.4 | 7.8 | 4.9 | 8.7 | 7.2 | 8.9 | 7.4 | 7.8 | 3.0 | 4.2 | 2.9 |
| Probable | 4.4 | 9.0 | 7.6 | 6.6 | 6.3 | 10.3 | 9.2 | 10.8 | 6.5 | 14.8 | 6.6 |
| Definite | 18.8 | 23.5 | 16.6 | 12.8 | 24.5 | 26.6 | 26.3 | 28.1 | 75.9 | 62.7 | 75.6 |
| Unifocal | 1.1 | 5.4 | 3.6 | 1.7 | 2.7 | 3.7 | 5.4 | 3.5 | 4.5 | 8.5 | 4.0 |
| Multifocal | 9.4 | 16.3 | 9.4 | 8.3 | 15.4 | 19.7 | 16.2 | 18.8 | 42.7 | 44.9 | 44.7 |
| Diffuse | 8.3 | 1.8 | 3.6 | 2.9 | 6.4 | 3.2 | 4.7 | 5.9 | 28.6 | 9.3 | 26.8 |
| Pre-PET vs. post-PET plans (%) | |||||||||||
| Nontreatment to treatment | 66 (36.5) | 78 (47.0) | 105 (47.1) | 956 (41.5) | 162 (20.7) | 119 (31.3) | 171 (26.2) | 1,656 (35.3) | 110 (55.3) | 112 (47.5) | 624 (48.1) |
| Nontreatment to nontreatment | 43 (23.8) | 25 (15.1) | 63 (28.3) | 433 (18.8) | 533 (68.2) | 220 (57.9) | 380 (58.2) | 1,829 (39.0) | 46 (23.1) | 82 (34.7) | 289 (22.3) |
| Treatment to treatment | 61 (33.7) | 51 (30.7) | 44 (19.7) | 800 (34.8) | 58 (7.4) | 23 (6.1) | 70 (10.7) | 814 (17.4) | 33 (16.6) | 31 (13.1) | 321 (24.7) |
| Treatment to nontreatment | 11 (6.1) | 12 (7.2) | 11 (4.9) | 112 (4.9) | 28 (3.6) | 18 (4.7) | 32 (4.9) | 387 (8.3) | 10 (5.0) | 11 (4.7) | 63 (4.9) |
| Impact on future actions | |||||||||||
| Avoid future diagnostic tests (%) | 81.2 | 89.8 | 77.6 | 72.0 | 84.4 | 88.4 | 84.5 | 76.5 | 85.9 | 89.4 | 80.9 |
NSCLC = non–small cell lung cancer.
Data in parentheses are percentages.